However, a recent real-world data study on 431 advanced cancer patients treated with PD-1/PD-L1 inhibitors revealed that (a) ≥grade 3/4 immune-related adverse events (irAEs) are affected by comorbidities including diabetes mellitus and others and that (b) patients with these ≥grade 3/4 irAEs revealed an improved progression-free survival (PFS) compared to patients without any adverse events [80]. Here, PDCD1 is linked to diabetes mellitus.